Agora Merger Sub

Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines administered via a room-temperature stable tablet. The company's proprietary VAAST (Vaxart Ad5 Antigen Systemic Technology) platform utilizes an adenoviral vector to deliver vaccine antigens and a potent TLR3 adjuvant to the small intestine, inducing both systemic and mucosal immune responses. Vaxart's lead programs include oral vaccines for norovirus, seasonal influenza, and COVID-19, the latter of which is supported by significant funding from BARDA's Project NextGen. The company aims to transform global vaccination by providing needle-free, shelf-stable alternatives to traditional injectable vaccines.